Carmen Criscitiello· @CarmenCriscit · X·· 20 小时前评分70
正文 · 原文
#ESMO26 @myESMO #ESMOAmbassords new data from Keynote-b49 👇🏼
26 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org🔥 KEYNOTE-B49 meets its primary endpoint, but benefit seems limited to few patients 👉 ICIs benefit selected ER+/HER2− BC pts (CPS≥10, ER-low) 👉 Are ADCs better ICI partners than CT? 👉 What about PD-1/VEGF bispecifics? ➡️ Better biomarkers urgently needed! #ESMO26在 X 查看被引用的帖子
来源：Carmen Criscitiello · x.com